oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2020-19-6-133-140oncotomsk-1652Research ArticleОБЗОРЫREVIEWSОНКОЛИТИЧЕСКАЯ ВИРОТЕРАПИЯ В ЛЕЧЕНИИ ГЛИОБЛАСТОМЫ: ДОСТИЖЕНИЯ И ПРОБЛЕМЫ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ (ОБЗОР ЛИТЕРАТУРЫ)ONCOLYTIC VIROTHERAPY IN GLIOBLASTOMA TREATMENT: PROGRESS AND CHALLENGES IN CLINICAL RESEARCH (LITERATURE REVIEW)https://orcid.org/0000-0003-3061-6108КитО. И.KitO. I.

доктор медицинских наук, профессор, член-корреспондент РАН, генеральный директор 

SPIN-код: 1728-0329. Researcher ID (WOS): U-2241-2017. Author ID (Scopus): 55994103100

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, General Director

Researcher ID (WOS): U-2241-2017. Author ID (Scopus): 55994103100

63, 14 liniya str., 344037, Rostov-on-don, Russia

https://orcid.org/0000-0001-8250-9617ИгнатовС. Н.IgnatovS. N.

врач-нейрохирург, аспирант

SPIN-код: 1734-0303

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

Postgraduate, Oncology Department

63, 14 liniya str., 344037, Rostov-on-don, Russia

ignatov_sergey_@mail.ruЗлатникЕ. Ю.ZlatnikE. Yu.

доктор медицинских наук, профессор, главный научный сотрудник лаборатории иммунофенотипирования опухолей

SPIN-код: 4137-7410. Author ID (Scopus): 6603160432

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, DSc, Professor, Chief Researcher, Immunophenotyping Laboratory of Tumors

Author ID (Scopus) 6603160432

63, 14 liniya str., 344037, Rostov-on-don, Russia

https://orcid.org/0000-0002-0118-4935СолдаткинаН. В.SoldatkinaN. V.

доктор медицинский наук, старший научный сотрудник отделения общей онкологии,SPIN: 8392-6679

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

63, 14 liniya str., 344037, Rostov-on-don, Russia

https://orcid.org/0000-0003-2937-0470РосторгуевЭ. Е.RostorguevE. E.

кандидат медицинских наук, заведующий отделением нейроонкологии

SPIN-код: 8487-9157. Author ID (Scopus): 57196005138 

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

63, 14 liniya str., 344037, Rostov-on-don, Russia

https://orcid.org/0000-0003-0874-5261СагакянцА. Б.SagakyantsA. B.

кандидат биологических наук, доцент, руководитель лаборатории иммунофенотипирования опухолей

SPIN-код: 7272-1408

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

63, 14 liniya str., 344037, Rostov-on-don, Russia

https://orcid.org/0000-0002-8522-1026БондаренкоЕ. С.BondarenkoE. S.

младший научный сотрудник лаборатории иммунофенотипирования опухолей

SPIN-код: 3117-4040

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

63, 14 liniya str., 344037, Rostov-on-don, Russia

https://orcid.org/0000-0002-6035-1756СитковскаяА. О.SitkovskayaA. O.

заведующая лабораторией клеточных технологий

SPIN–код: 1659-6976. Researcher ID: E-7496-2018. Author ID (Scopus): 56381527400

Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

Head of the Laboratory of Cell Technologies

Researcher ID: E-7496-2018. Author ID (Scopus): 56381527400

63, 14 liniya str., 344037, Rostov-on-don, Russia

ФГБУ «Национальный медицинский исследовательский центр онкологии Минздрава России»РоссияNational Medical Research Center of OncologyRussian Federation202030122020196133140Copyright © Кит О.И., Игнатов С.Н., Златник Е.Ю., Солдаткина Н.В., Росторгуев Э.Е., Сагакянц А.Б., Бондаренко Е.С., Ситковская А.О., 20202020Кит О.И., Игнатов С.Н., Златник Е.Ю., Солдаткина Н.В., Росторгуев Э.Е., Сагакянц А.Б., Бондаренко Е.С., Ситковская А.О.Kit O.I., Ignatov S.N., Zlatnik E.Y., Soldatkina N.V., Rostorguev E.E., Sagakyants A.B., Bondarenko E.S., Sitkovskaya A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1652

Glial tumors comprise about 60 % of primary malignant brain tumors, and 70 % of them show morphological signs of high-grade cancer (High Grade Gliomas III , IV WHO 2016) [1, 2]. Despite a significant technical pre- and intraoperative progress as well as advances in radiotherapy and chemotherapy, the overall median survival is very low, being less than 20 months [3] and less than 12 months in patients with relapse [4]. Recent studies have shown that chemo- and radioresistance is due to the existence of cancer stem cells [5, 6]. Poor treatment outcomes require the development and implementation of new approaches to the treatment of highgrade gliomas. In recent years, increasing attention has been paid to the development of immunotherapeutic treatment approaches, including the development of oncolytic virotherapy. Tropism to target cancer cells, as well as various viral vectors, has been developed using methods of genetic engineering; synergism of viruses and adjuvant therapy has been studied. Despite extensive experimental studies of the mechanism of oncolysis [1], there are only a few reports on Phase I–II clinical trials. This review considers the most successful applications of oncolytic viruses in relation to glioblastoma in animal models and their translation into clinical practice in patients.

онколитическая виротерапияглиобластомаглиома высокой степени злокачественностиoncolytic virotherapyglioblastomahigh grade gliomasReferencesБаклаушев В.П., Горяйнов С.А., Павлова Г.В., Потапов А.А., Чехонин В.П. Онколитические вирусы в лечении низкодифференцированных глиом. Клиническая практика. 2015; 2: 46–59.Baklaushev V.P., Gorjajnov S.A., Pavlova G.V., Potapov A.A., Chehonin V.P. Oncolytic viruses in high–grade gliomas treatment. Clinical Practice. 2015; 2: 46–59. (in Russian).Foreman P.M., Friedman G.K., Cassady K.A., Markert J.M. Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics. 2017 Apr; 14(2): 333–344. doi: 10.1007/s13311-017-0516-0.Foreman P.M., Friedman G.K., Cassady K.A., Markert J.M. Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics. 2017 Apr; 14(2): 333–344. doi: 10.1007/s13311-017-0516-0.Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., Werner-Wasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699–708. doi: 10.1056/NEJMoa1308573.Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., Werner-Wasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699–708. doi: 10.1056/NEJMoa1308573.Taal W., Oosterkamp H.M., Walenkamp A.M., Dubbink H.J., Beerepoot L.V., Hanse M.C., Buter J., Honkoop A.H., Boerman D., de Vos F.Y., Dinjens W.N., Enting R.H., Taphoorn M.J., van den Berkmortel F.W., Jansen R.L., Brandsma D., Bromberg J.E., van Heuvel I., Vernhout R.M., van der Holt B., van den Bent M.J. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014 Aug; 15(9): 943–53. doi: 10.1016/S1470-2045(14)70314-6.Taal W., Oosterkamp H.M., Walenkamp A.M., Dubbink H.J., Beerepoot L.V., Hanse M.C., Buter J., Honkoop A.H., Boerman D., de Vos F.Y., Dinjens W.N., Enting R.H., Taphoorn M.J., van den Berkmortel F.W., Jansen R.L., Brandsma D., Bromberg J.E., van Heuvel I., Vernhout R.M., van der Holt B., van den Bent M.J. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014 Aug; 15(9): 943–53. doi: 10.1016/S1470-2045(14)70314-6.Batlle E., Clevers H. Cancer stem cells revisited. Nat Med. 2017 Oct 6; 23(10): 11241134. doi: 10.1038/nm.4409.Batlle E., Clevers H. Cancer stem cells revisited. Nat Med. 2017 Oct 6; 23(10): 11241134. doi: 10.1038/nm.4409.Bischof J., Westhoff M.A., Wagner J.E., Halatsch M.E., Trentmann S., Knippschild U., Wirtz C.R., Burster T. Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells. Tumour Biol. 2017 Mar; 39(3): 1010428317692227. doi: 10.1177/1010428317692227.Bischof J., Westhoff M.A., Wagner J.E., Halatsch M.E., Trentmann S., Knippschild U., Wirtz C.R., Burster T. Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells. Tumour Biol. 2017 Mar; 39(3): 1010428317692227. doi: 10.1177/1010428317692227.Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М., 2018. 250 с.Kaprin A.D., Starinskij V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow, 2018. 250 p. (in Russian).Hulou M.M., Cho C.F., Chiocca E.A., Bjerkvig R. Еxperimental therapies: gene therapies and oncolytic viruses. Handb Clin Neurol. 2016; 134: 183–97. doi: 10.1016/B978-0-12-802997-8.00011-6.Hulou M.M., Cho C.F., Chiocca E.A., Bjerkvig R. Еxperimental therapies: gene therapies and oncolytic viruses. Handb Clin Neurol. 2016; 134: 183–97. doi: 10.1016/B978-0-12-802997-8.00011-6.Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 7; 444(7120): 756–60. doi: 10.1038/nature05236.Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 7; 444(7120): 756–60. doi: 10.1038/nature05236.Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature. 2004 Nov 18; 432(7015): 396–401. doi: 10.1038/nature03128.Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature. 2004 Nov 18; 432(7015): 396–401. doi: 10.1038/nature03128.Kaufmann J.K., Chiocca E.A. Glioma virus therapies between bench and bedside. Neuro Oncol. 2014 Mar; 16(3): 334–51. doi: 10.1093/neuonc/not310.Kaufmann J.K., Chiocca E.A. Glioma virus therapies between bench and bedside. Neuro Oncol. 2014 Mar; 16(3): 334–51. doi: 10.1093/neuonc/not310.Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991 May 10; 252(5007): 854–6. doi: 10.1126/science.1851332.Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991 May 10; 252(5007): 854–6. doi: 10.1126/science.1851332.Wollmann G., Tattersall P., van den Pol A.N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol. 2005 May; 79(10): 6005–22. doi: 10.1128/JVI.79.10.6005-6022.2005.Wollmann G., Tattersall P., van den Pol A.N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol. 2005 May; 79(10): 6005–22. doi: 10.1128/JVI.79.10.6005-6022.2005.Freeman A.I., Zakay-Rones Z., Gomori J.M., Linetsky E., Rasooly L., Greenbaum E., Rozenman-Yair S., Panet A., Libson E., Irving C.S., Galun E., Siegal T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006; 13(1): 221–8. doi: 10.1016/j.ymthe.2005.08.016.Freeman A.I., Zakay-Rones Z., Gomori J.M., Linetsky E., Rasooly L., Greenbaum E., Rozenman-Yair S., Panet A., Libson E., Irving C.S., Galun E., Siegal T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006; 13(1): 221–8. doi: 10.1016/j.ymthe.2005.08.016.Manservigi R., Argnani R., Marconi P. HSV Recombinant Vectors for Gene Therapy. Open Virol J. 2010; 4: 123–56. doi: 10.2174/1874357901004030123.Manservigi R., Argnani R., Marconi P. HSV Recombinant Vectors for Gene Therapy. Open Virol J. 2010; 4: 123–56. doi: 10.2174/1874357901004030123.McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Montalto G., Cervello M., Nicoletti F., Fagone P., Malaponte G., Mazzarino M.C., Candido S., Libra M., Bäsecke J., Mijatovic S., MaksimovicIvanic D., Milella M., Tafuri A., Cocco L., Evangelisti C., Chiarini F., Martelli A.M. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012 Sep; 3(9): 954–87. doi: 10.18632/oncotarget.652.McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Montalto G., Cervello M., Nicoletti F., Fagone P., Malaponte G., Mazzarino M.C., Candido S., Libra M., Bäsecke J., Mijatovic S., MaksimovicIvanic D., Milella M., Tafuri A., Cocco L., Evangelisti C., Chiarini F., Martelli A.M. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012 Sep; 3(9): 954–87. doi: 10.18632/oncotarget.652.Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A.Jr., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26; 321(5897): 1807–12. doi: 10.1126/science.1164382.Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A.Jr., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26; 321(5897): 1807–12. doi: 10.1126/science.1164382.Gallia G.L., Tyler B.M., Hann C.L., Siu I.M., Giranda V.L., Vescovi A.L., Brem H., Riggins G.J. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009 Feb; 8(2): 386–93. doi: 10.1158/1535-7163.MCT-08-0680.Gallia G.L., Tyler B.M., Hann C.L., Siu I.M., Giranda V.L., Vescovi A.L., Brem H., Riggins G.J. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 2009 Feb; 8(2): 386–93. doi: 10.1158/1535-7163.MCT-08-0680.Kanai R., Wakimoto H., Martuza R.L., Rabkin S.D. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 1; 17(11): 3686–96. doi: 10.1158/1078-0432.CCR-10-3142.Kanai R., Wakimoto H., Martuza R.L., Rabkin S.D. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 1; 17(11): 3686–96. doi: 10.1158/1078-0432.CCR-10-3142.Whisenhunt T.R. Jr., Rajneesh K.F., Hackney J.R., Markert J.M. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytic Virother. 2015 Jan 30; 4: 33–8. doi: 10.2147/OV.S62461.Whisenhunt T.R. Jr., Rajneesh K.F., Hackney J.R., Markert J.M. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. Oncolytic Virother. 2015 Jan 30; 4: 33–8. doi: 10.2147/OV.S62461.Parker J.N., Bauer D.F., Cody J.J., Markert J.M. Oncolytic viral therapy of malignant glioma. Neurotherapeutics. 2009; 6(3): 558–69. doi: 10.1016/j.nurt.2009.04.011.Parker J.N., Bauer D.F., Cody J.J., Markert J.M. Oncolytic viral therapy of malignant glioma. Neurotherapeutics. 2009; 6(3): 558–69. doi: 10.1016/j.nurt.2009.04.011.Friedman G.K., Pressey J.G., Reddy A.T., Markert J.M., Gillespie G.Y. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 2009 Jul; 17(7): 1125–35. doi: 10.1038/mt.2009.73.Friedman G.K., Pressey J.G., Reddy A.T., Markert J.M., Gillespie G.Y. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 2009 Jul; 17(7): 1125–35. doi: 10.1038/mt.2009.73.Lu X. Impact of IL-12 in Cancer. Curr Cancer Drug Targets. 2017; 17(8): 682–697. doi: 10.2174/1568009617666170427102729.Lu X. Impact of IL-12 in Cancer. Curr Cancer Drug Targets. 2017; 17(8): 682–697. doi: 10.2174/1568009617666170427102729.Chiu T.L., Wang M.J., Su C.C. The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model. J Biomed Sci. 2012; 19(1): 45. doi: 10.1186/1423-0127-19-45.Chiu T.L., Wang M.J., Su C.C. The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model. J Biomed Sci. 2012; 19(1): 45. doi: 10.1186/1423-0127-19-45.Patel D.M., Foreman P.M., Nabors L.B., Riley K.O., Gillespie G.Y., Markert J.M. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev. 2016 Jun; 27(2): 69–78. doi: 10.1089/humc.2016.031.Patel D.M., Foreman P.M., Nabors L.B., Riley K.O., Gillespie G.Y., Markert J.M. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev. 2016 Jun; 27(2): 69–78. doi: 10.1089/humc.2016.031.Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells. 2008 Jun 30; 25(4): 462–6.Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells. 2008 Jun 30; 25(4): 462–6.Geoerger B., Vassal G., Opolon P., Dirven C.M., Morizet J., Laudani L., Grill J., Giaccone G., Vandertop W.P., Gerritsen W.R., van Beusechem V.W. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res. 2004 Aug 15; 64(16): 5753–9. doi: 10.1158/0008-5472. CAN-04-0499.Geoerger B., Vassal G., Opolon P., Dirven C.M., Morizet J., Laudani L., Grill J., Giaccone G., Vandertop W.P., Gerritsen W.R., van Beusechem V.W. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res. 2004 Aug 15; 64(16): 5753–9. doi: 10.1158/0008-5472. CAN-04-0499.Lun X., Yang W., Alain T., Shi Z.Q., Muzik H., Barrett J.W., McFadden G., Bell J., Hamilton M.G., Senger D.L., Forsyth P.A. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 2005; 65(21): 9982–90. doi: 10.1158/0008-5472.CAN-05-1201.Lun X., Yang W., Alain T., Shi Z.Q., Muzik H., Barrett J.W., McFadden G., Bell J., Hamilton M.G., Senger D.L., Forsyth P.A. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 2005; 65(21): 9982–90. doi: 10.1158/0008-5472.CAN-05-1201.Lun X., Alain T., Zemp F.J., Zhou H., Rahman M.M., Hamilton M.G., McFadden G., Bell J., Senger D.L., Forsyth P.A. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res. 2010 Jan 15; 70(2): 598–608. doi: 10.1158/0008-5472.CAN-09-1510.Lun X., Alain T., Zemp F.J., Zhou H., Rahman M.M., Hamilton M.G., McFadden G., Bell J., Senger D.L., Forsyth P.A. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res. 2010 Jan 15; 70(2): 598–608. doi: 10.1158/0008-5472.CAN-09-1510.Lun X.Q., Zhou H., Alain T., Sun B., Wang L., Barrett J.W., Stanford M.M., McFadden G., Bell J., Senger D.L., Forsyth P.A. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 2007 Sep 15; 67(18): 8818–27. doi: 10.1158/0008-5472.CAN-07-1214.Lun X.Q., Zhou H., Alain T., Sun B., Wang L., Barrett J.W., Stanford M.M., McFadden G., Bell J., Senger D.L., Forsyth P.A. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 2007 Sep 15; 67(18): 8818–27. doi: 10.1158/0008-5472.CAN-07-1214.Zemp F.J., Lun X., McKenzie B.A., Zhou H., Maxwell L., Sun B., Kelly J.J., Stechishin O., Luchman A., Weiss S., Cairncross J.G., Hamilton M.G., Rabinovich B.A., Rahman M.M., Mohamed M.R., Smallwood S., Senger D.L., Bell J., McFadden G., Forsyth P.A. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol. 2013 Jul; 15(7): 904–20. doi: 10.1093/neuonc/not035.Zemp F.J., Lun X., McKenzie B.A., Zhou H., Maxwell L., Sun B., Kelly J.J., Stechishin O., Luchman A., Weiss S., Cairncross J.G., Hamilton M.G., Rabinovich B.A., Rahman M.M., Mohamed M.R., Smallwood S., Senger D.L., Bell J., McFadden G., Forsyth P.A. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol. 2013 Jul; 15(7): 904–20. doi: 10.1093/neuonc/not035.Naaman H., Rabinski T., Yizhak A., Mizrahi S., Avni Y.S., Taube R., Rager B., Weinstein Y., Rall G., Gopas J., Ofir R. Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells. Cell Reprogram. 2018; 20(1): 17–26. doi: 10.1089/cell.2017.0034.Naaman H., Rabinski T., Yizhak A., Mizrahi S., Avni Y.S., Taube R., Rager B., Weinstein Y., Rall G., Gopas J., Ofir R. Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells. Cell Reprogram. 2018; 20(1): 17–26. doi: 10.1089/cell.2017.0034.Yanagi Y., Takeda M., Ohno S., Hashiguchi T. Measles virus receptors. Curr Microbiol Immunol. 2009; 329: 13–30. doi: 10.1007/978-3-540-70523-9_2.Yanagi Y., Takeda M., Ohno S., Hashiguchi T. Measles virus receptors. Curr Microbiol Immunol. 2009; 329: 13–30. doi: 10.1007/978-3-540-70523-9_2.Ulasov I.V., Tyler M.A., Zheng S., Han Y., Lesniak M.S. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther. 2006 May; 17(5): 556–64. doi: 10.1089/hum.2006.17.556.Ulasov I.V., Tyler M.A., Zheng S., Han Y., Lesniak M.S. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther. 2006 May; 17(5): 556–64. doi: 10.1089/hum.2006.17.556.Peng K.W., TenEyck C.J., Galanis E., Kalli K.R., Hartmann L.C., Russell S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002 Aug 15; 62(16): 4656–62.Peng K.W., TenEyck C.J., Galanis E., Kalli K.R., Hartmann L.C., Russell S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002 Aug 15; 62(16): 4656–62.Peng K.W., Facteau S., Wegman T., O'Kane D., Russell S.J. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002 May; 8(5): 527–31. doi: 10.1038/nm0502-527.Peng K.W., Facteau S., Wegman T., O'Kane D., Russell S.J. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002 May; 8(5): 527–31. doi: 10.1038/nm0502-527.Giannini C., Sarkaria J.N., Saito A., Uhm J.H., Galanis E., Carlson B.L., Schroeder M.A., James C.D. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005; 7(2): 164–76. doi: 10.1215/S1152851704000821.Giannini C., Sarkaria J.N., Saito A., Uhm J.H., Galanis E., Carlson B.L., Schroeder M.A., James C.D. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005; 7(2): 164–76. doi: 10.1215/S1152851704000821.Myers R., Harvey M., Kaufmann T.J., Greiner S.M., Krempski J.W., Raffel C., Shelton S.E., Soeffker D., Zollman P., Federspiel M.J., Blanco M., Galanis E. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther. 2008 Jul; 19(7): 690–8. doi: 10.1089/hum.2008.035.Myers R., Harvey M., Kaufmann T.J., Greiner S.M., Krempski J.W., Raffel C., Shelton S.E., Soeffker D., Zollman P., Federspiel M.J., Blanco M., Galanis E. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther. 2008 Jul; 19(7): 690–8. doi: 10.1089/hum.2008.035.Allen C., Paraskevakou G., Liu C., Iankov I.D., Msaouel P., Zollman P., Myers R., Peng K.W., Russell S.J., Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther. 2008 Feb; 8(2): 213–20. doi: 10.1517/14712598.8.2.213.Allen C., Paraskevakou G., Liu C., Iankov I.D., Msaouel P., Zollman P., Myers R., Peng K.W., Russell S.J., Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther. 2008 Feb; 8(2): 213–20. doi: 10.1517/14712598.8.2.213.Singh S.K., Clarke I.D., Hide T., Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene. 2004; 23(43): 7267–73. doi: 10.1038/sj.onc.1207946.Singh S.K., Clarke I.D., Hide T., Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene. 2004; 23(43): 7267–73. doi: 10.1038/sj.onc.1207946.Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B., Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008 Jan 1; 14(1): 123–9. doi: 10.1158/1078-0432.CCR-07-0932.Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B., Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008 Jan 1; 14(1): 123–9. doi: 10.1158/1078-0432.CCR-07-0932.Bach P., Abel T., Hoffmann C., Gal Z., Braun G., Voelker I., Ball C.R., Johnston I.C., Lauer U.M., Herold-Mende C., Mühlebach M.D., Glimm H., Buchholz C.J. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res. 2013 Jan 15; 73(2): 865–74. doi: 10.1158/0008-5472.CAN-12-2221.Bach P., Abel T., Hoffmann C., Gal Z., Braun G., Voelker I., Ball C.R., Johnston I.C., Lauer U.M., Herold-Mende C., Mühlebach M.D., Glimm H., Buchholz C.J. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res. 2013 Jan 15; 73(2): 865–74. doi: 10.1158/0008-5472.CAN-12-2221.Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8): 709–22. doi: 10.1056/NEJMoa1308345.Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8): 709–22. doi: 10.1056/NEJMoa1308345.Desjardins A., Gromeier M., Herndon J.E. 2nd, Beaubier N., Bolognesi D.P., Friedman A.H., Friedman H.S., McSherry F., Muscat A.M., Nair S., Peters K.B., Randazzo D., Sampson J.H., Vlahovic G., Harrison W.T., McLendon R.E., Ashley D., Bigner D.D. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018; 379(2): 150–161. doi: 10.1056/NEJMoa1716435.Desjardins A., Gromeier M., Herndon J.E. 2nd, Beaubier N., Bolognesi D.P., Friedman A.H., Friedman H.S., McSherry F., Muscat A.M., Nair S., Peters K.B., Randazzo D., Sampson J.H., Vlahovic G., Harrison W.T., McLendon R.E., Ashley D., Bigner D.D. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018; 379(2): 150–161. doi: 10.1056/NEJMoa1716435.Geletneky K., Hajda J., Angelova A.L., Leuchs B., Capper D., Bartsch A.J., Neumann J.O., Schöning T., Hüsing J., Beelte B., Kiprianova I., Roscher M., Bhat R., von Deimling A., Brück W., Just A., Frehtman V., Löbhard S., Terletskaia-Ladwig E., Fry J., Jochims K., Daniel V., Krebs O., Dahm M., Huber B., Unterberg A., Rommelaere J. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Mol Ther. 2017; 25(12): 2620–34. doi: 10.1016/j.ymthe.2017.08.016.Geletneky K., Hajda J., Angelova A.L., Leuchs B., Capper D., Bartsch A.J., Neumann J.O., Schöning T., Hüsing J., Beelte B., Kiprianova I., Roscher M., Bhat R., von Deimling A., Brück W., Just A., Frehtman V., Löbhard S., Terletskaia-Ladwig E., Fry J., Jochims K., Daniel V., Krebs O., Dahm M., Huber B., Unterberg A., Rommelaere J. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Mol Ther. 2017; 25(12): 2620–34. doi: 10.1016/j.ymthe.2017.08.016.Kuo L., Godeke G.J., Raamsman M.J., Masters P.S., Rottier P.J. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol. 2000 Feb; 74(3): 1393–406. doi: 10.1128/jvi.74.3.1393-1406.2000.Kuo L., Godeke G.J., Raamsman M.J., Masters P.S., Rottier P.J. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol. 2000 Feb; 74(3): 1393–406. doi: 10.1128/jvi.74.3.1393-1406.2000.Yount B., Denison M.R., Weiss S.R., Baric R.S. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol. 2002 Nov; 76(21): 11065–78. doi: 10.1128/jvi.76.21.11065-11078.2002.Yount B., Denison M.R., Weiss S.R., Baric R.S. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol. 2002 Nov; 76(21): 11065–78. doi: 10.1128/jvi.76.21.11065-11078.2002.Verheije M.H., Lamfers M.L., Würdinger T., Grinwis G.C., Gerritsen W.R., van Beusechem V.W., Rottier P.J. Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. J Virol. 2009; 83(15): 7507–16. doi: 10.1128/JVI.00495-09.Verheije M.H., Lamfers M.L., Würdinger T., Grinwis G.C., Gerritsen W.R., van Beusechem V.W., Rottier P.J. Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. J Virol. 2009; 83(15): 7507–16. doi: 10.1128/JVI.00495-09.Zhu Z., Gorman M.J., McKenzie L.D., Chai J.N., Hubert C.G., Prager B.C., Fernandez E., Richner J.M., Zhang R., Shan C., Tycksen E., Wang X., Shi P.Y., Diamond M.S., Rich J.N., Chheda M.G. Correction: Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017; 214(10): 3145. doi: 10.1084/jem.2017109309122017c.Zhu Z., Gorman M.J., McKenzie L.D., Chai J.N., Hubert C.G., Prager B.C., Fernandez E., Richner J.M., Zhang R., Shan C., Tycksen E., Wang X., Shi P.Y., Diamond M.S., Rich J.N., Chheda M.G. Correction: Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017; 214(10): 3145. doi: 10.1084/jem.2017109309122017c.Сосновцева А.О., Гриненко Н.Ф., Липатова А.В.,Чумаков П.М., Чехонин В.П. Онколитические вирусы в терапии злокачественных глиом. Биомедицинская химия. 2016; 62 (4): 376–390.Sosnovceva A.O., Grinenko N.F., Lipatova A.V.,Chumakov P.M., Chehonin V.P. Oncolytic viruses in the therapy of malignant gliomas. Biomedical Chemistry. 2016; 2 (4): 373–390. (In Russian).Губанова Н.В., Гайтан А.С., Разумов И.А., Мордвинов В.А., Кривошапкин А.Л., Нетесов С.В., Чумаков П.М. Онколитические вирусы в терапии глиом. Молекулярная биология. 2012; 46(6): 874–886.Gubanova N.V., Gajtan A.S., Razumov I.A., Mordvinov V.A., Krivoshapkin A.L., Netesov S.V., Chumakov P.M. Oncolytic viruses in the therapy of gliomas. Molecular biology. 2012; 46 (6): 874–886. (in Russian).

The authors declare that there are no conflicts of interest present.